To compare the efficacy of lamivudine vs placebo vs lamivudine followed by the combination of lamivudine plus Intron A in patients with chronic hepatitis B infection who are alpha interferon nonresponders with regard to improvements in liver histology and HBeAG seroconversion rates; and, to evalute the safety of the three treatment regimens.
Showing the most recent 10 out of 563 publications